WeTrials
Completed

A Randomized, Double-blind, Phase 2, Dose-finding Trial of Once Weekly Petrelintide Compared With Placebo in Participants With Obesity or Overweight With Weight Related Comorbidities

What is this study?

This study is testing an experimental medication called petrelintide to see how well it helps people lose weight and how safe it is compared to a placebo. Researchers want to find the best dose to help adults manage their weight and improve their overall health.

Who can participate?

You might be eligible if you are an adult with a higher body mass index, or a BMI of 27 or higher along with a health condition like high blood pressure or abnormal cholesterol. Participants cannot have diabetes, take blood sugar medications, or have used other weight loss products recently.

What will happen?

During the study, you will receive either the study drug or an inactive placebo as a weekly injection that you give to yourself using a small syringe. The medical team will closely monitor your weight, health, and how well you tolerate the medication.

Where and when?

This completed study took place at research locations in Birmingham, Alabama, as well as Boca Raton and Clearwater, Florida. It has finished collecting its data.

Key Points
  • 1Testing petrelintide for weight management compared to a placebo
  • 2Involves taking weekly injections yourself using a small syringe
  • 3Designed for adults with high BMI and related health conditions but no diabetes

Related video

HCPLive: lead investigator Timothy Garvey on the ZUPREME-1 petrelintide phase 2 results (2026)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Obesity

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.